| 21.01 -5.01 (-19.25%) | 02-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 38.45 |
1-year : | 47.66 |
| Resists | First : | 32.92 |
Second : | 40.81 |
| Pivot price | 25.7 |
|||
| Supports | First : | 20.16 |
Second : | 16.77 |
| MAs | MA(5) : | 25.95 |
MA(20) : | 27.5 |
| MA(100) : | 21.83 |
MA(250) : | 18.8 |
|
| MACD | MACD : | -2.1 |
Signal : | -1.9 |
| %K %D | K(14,3) : | 30.3 |
D(3) : | 40.2 |
| RSI | RSI(14): 34.1 |
|||
| 52-week | High : | 46.79 | Low : | 6.76 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ALGS ] has closed below the lower bollinger band by 2.0%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 24.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 26.41 - 26.58 | 26.58 - 26.7 |
| Low: | 19.85 - 20.01 | 20.01 - 20.13 |
| Close: | 20.79 - 21.04 | 21.04 - 21.21 |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Wed, 12 Feb 2025
Aligos Therapeutics secures $105 million in private placement - Investing.com India
Wed, 12 Feb 2025
Major Funding Alert: Aligos Lands $105M Investment for Game-Changing Hepatitis B Drug Development - StockTitan
Sat, 08 Feb 2025
Here's Why Aligos Therapeutics (NASDAQ:ALGS) Must Use Its Cash Wisely - Yahoo Canada Finance
Mon, 03 Feb 2025
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Update - MarketBeat
Mon, 20 Jan 2025
Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Thu, 16 Jan 2025
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Update - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 419890 (%) |
| Held by Institutions | 17.7 (%) |
| Shares Short | 457 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.268e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 586.3 % |
| Return on Equity (ttm) | -67.4 % |
| Qtrly Rev. Growth | 6e+006 % |
| Gross Profit (p.s.) | -28.68 |
| Sales Per Share | -69.2 |
| EBITDA (p.s.) | -3.32547e+007 |
| Qtrly Earnings Growth | -7.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -85 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.31 |
| Price to Cash Flow | 2.95 |
| Dividend | 0 |
| Forward Dividend | 664380 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|